Post-transplant lymphoproliferative disorder: No relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients

Danielle K. Longmore, Louise S. Conwell, John R. Burke, Stephen McDonald, Steven J. McTaggart

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


PTLD is a potentially life-limiting complication of pediatric transplantation. Previous registry-based studies in renal transplantation have suggested a link between rhGH use and PTLD. In this study, demographic and transplant data on those aged <18 yr and transplanted between 1991 and 2008 were collected from the ANZDATA Registry. Associations between gender, age at time of transplant, recipient CMV and EBV status, use of monoclonal antibody therapy, and use of rhGH were studied as potential predictors of PTLD. Among 650 transplants, there were 20 cases (3.1%) of PTLD, with half presenting within two yr post-transplant. Eight patients exposed to rhGH at any time developed PTLD, and this association was not statistically significant (RR = 1.5[0.6-3.4], p = 0.36). On multivariate analysis, there were no significant predictors for PTLD. In this study, previously identified potential risk factors were not identified as significant predictors for the development of PTLD. Although limited sample size may affect our ability to infer safety, this large retrospective cohort study does not suggest an increased risk of PTLD in pediatric kidney transplant recipients who received rhGH treatment.

Original languageEnglish
Pages (from-to)731-736
Number of pages6
JournalPediatric Transplantation
Issue number8
Publication statusPublished or Issued - Dec 2013


  • Australian and New Zealand Dialysis and Transplant Registry
  • kidney transplantation
  • pediatrics
  • post-transplant lymphoproliferative disease
  • recombinant human growth hormone
  • renal transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this